Testicular seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Schmoll
H-J
HJ
Department of Oncology/Haematology/Haemostaseology, University Hospital Halle, Germany.
Jordan
K
K
Huddart
R
R
Pes
M P Laguna
MP
Horwich
A
A
Fizazi
K
K
Kataja
V
V
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001706:Biopsy; D002278:Carcinoma in Situ / Q000473:pathology; D018997:Chorionic Gonadotropin, beta Subunit, Human / Q000097:blood; D003131:Combined Modality Therapy; D005060:Europe / Q000453:epidemiology; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D007770:L-Lactate Dehydrogenase / Q000097:blood; D008297:Male; D009362:Neoplasm Metastasis / Q000628:therapy; D009367:Neoplasm Staging; D009919:Orchiectomy; D011878:Radiotherapy; D018570:Risk Assessment; D016879:Salvage Therapy; D055502:Secondary Prevention; D018239:Seminoma / Q000175:diagnosis* / Q000473:pathology / Q000628:therapy*; D013736:Testicular Neoplasms / Q000175:diagnosis* / Q000473:pathology / Q000628:therapy*; D016896:Treatment Outcome; D000509:alpha-Fetoproteins / Q000032:analysis
D018997:Chorionic Gonadotropin, beta Subunit, Human; D000509:alpha-Fetoproteins; D007770:L-Lactate Dehydrogenase